Detection of oxycodone and oxymorphone in urine
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
OXYCU | Oxycodone w/metabolite Conf, U | Yes | No |
Testing begins with the screening assay. If the oxycodone screen is positive, then the liquid chromatography tandem mass spectrometry confirmation with quantification will be performed at an additional charge.
Immunoassay
Oxycodone (Oxycontin, Percodan)
Oxycontin (Oxycodone)
Oxymorphone
Percodan (Oxycodone)
Testing begins with the screening assay. If the oxycodone screen is positive, then the liquid chromatography tandem mass spectrometry confirmation with quantification will be performed at an additional charge.
Urine
For situations where chain of custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody testing, order OXYSX / Oxycodone Screen, Chain of Custody, Random, Urine.
Additional drug panels and specific requests are available; call 800-533-1710 or 507-266-5700.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Plastic urine container
Submission Container/Tube: Plastic, 5 mL tube
Specimen Volume: 2 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative.
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
0.5 mL
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Refrigerated (preferred) | 14 days | |
Frozen | 14 days | ||
Ambient | 72 hours |
Detection of oxycodone and oxymorphone in urine
Testing begins with the screening assay. If the oxycodone screen is positive, then the liquid chromatography tandem mass spectrometry confirmation with quantification will be performed at an additional charge.
Opiates are the natural or synthetic drugs that have a morphine-like pharmacological action. Medically, opiates are used primarily for relief of pain. Opiates include morphine and drugs structurally similar to morphine (eg, codeine).
Oxycodone is metabolized to noroxycodone, oxymorphone and their glucuronides and is excreted primarily via the kidney. The presence of oxycodone indicates exposure to oxycodone within 2 to 3 days prior to specimen collection.
Oxymorphone is metabolized in the liver and excreted via the kidney primarily as the glucuronide conjugates. Oxymorphone is also a metabolite of oxycodone and, therefore, the presence of oxymorphone could also indicate exposure to oxycodone.
Negative
Screening cutoff concentration:
Oxycodone: 100 ng/mL
A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, OXYCU / Oxycodone with Metabolite Confirmation, Random, Urine) for more information.
For information about drug testing, including estimated detection times, see Drugs of Abuse Testing.
Other drugs in the opioid class, such as fentanyl, meperidine, methadone, and opiate antagonists such as naloxone, are not detected.
1. Anderson DT, Fritz KL, Muto JJ. Oxycontin: the concept of a "ghost pill" and the postmortem tissue distribution of oxycodone in 36 cases. J Anal Toxicol. 2002;26(7):448-459. doi:10.1093/jat/26.7.448
2. Jannetto PJ, Gock SG. Oxycodone: Recognition and Pharmacogenomics. Clinical and Forensic Toxicology News, 2003 March
3. Cone EJ, Fant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths: A DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol. 2003;27(2):57-67. doi:10.1093/jat/27.2.57
4. Baselt RC, Cravey RH. Oxycodone. In: Disposition of Toxic Drugs and Chemicals in Man. 4th ed. Chemical Toxicology Institute; 1995:572-574
5. Langman LJ, Bechtel LK, Holstege CP. Clinical toxicology. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:454
Oxycodone and its metabolite, oxymorphone, are analyzed via immunoassay. The assay uses specific antibodies that can detect oxycodone and oxymorphone without any significant cross-reactivity to other opiate compounds. The assay is based on the competition between a drug labeled with glucose-6-phosphate dehydrogenase (G6PD), and free drug from the urine sample for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, the specific antibody binds the drug labeled with G6PD and causes a decrease in enzyme activity. This phenomenon creates a direct relationship between the drug concentration in urine and enzyme activity. The enzyme activity is determined spectrophotometrically at 340 nm by measuring the conversion of nicotinamide adenine dinucleotide (NAD+) to NADH.(Package insert: Oxycodone. Roche Diagnostics; 12/2016)
Monday through Saturday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
80307
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
OXYSU | Oxycodone Screen, U | 19642-8 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
62623 | Oxycodone | 19642-8 |